Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Tempest Therapeutics Inc

TPST ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.02

▼ -13.25%

Market Cap $16.22M · Vol 32.13K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$16.22M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+78.83%

YoY

RSI (14)

55.80

Momentum

Beta

-1.59

vs Market

52W High

$12.22

91.69% below

52W Low

$0.85

19.41% above

Volume

32.13K

Avg 19.36K

P/B

2.12

Price-to-book

ROE

N/A

Return on equity

Free Float

68.22%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Tempest Therapeutics Inc (TPST) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TPST pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+10.72%

+3.52%

-51.44%

-56.99%

YTD

-64.63%

-89.29%

-88.35%

-99.41%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-26,262,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-89.91% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.12
P/FCF	N/A
EPS Growth	+78.83%
Outstanding Shares	15.98M

Technical Indicators

50-Day SMA	$1.07
200-Day SMA	$2.65
RSI (14)	55.80
Beta	-1.59
52-Week High	$12.22
52-Week Low	$0.85

Volume Today	32.13K
Avg Daily Volume (30D)	19.36K
Relative Volume	1.66x
Volatility (10D)	115.03
Volatility (30D)	86.05
Free Float	68.22%

Analyst Consensus

BUY

Current Price $1.02

Mean Target $11.00

52W Low$0.85 52W High$12.22

Current

Target

$0.85 $12.22

Current Analyst target

+983.74% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG002NDK348

ISINUS87978U2078

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 8, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.